NYSE · BHC
Healthcare · Drug Manufacturers - Specialty & Generic
$5.69
Up+$0.04 (+0.71%)
Updated Sep 26, 2026, 5:04 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BHC closed at $5.69 after 20 trading sessions, down 9.97% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $5.66 | $5.83 | $5.63 | $5.69 | 1.25M |
| Sep 24, 2026 | $5.67 | $5.78 | $5.54 | $5.65 | 2.02M |
| Sep 23, 2026 | $5.82 | $5.925 | $5.67 | $5.71 | 1.82M |
| Sep 22, 2026 | $5.755 | $5.82 | $5.615 | $5.81 | 1.91M |
| Sep 21, 2026 | $5.67 | $5.74 | $5.555 | $5.64 | 1.54M |
| Sep 18, 2026 | $5.68 | $5.725 | $5.60 | $5.67 | 1.91M |
| Sep 17, 2026 | $5.78 | $5.78 | $5.625 | $5.65 | 2.87M |
| Sep 16, 2026 | $5.69 | $5.825 | $5.645 | $5.69 | 1.57M |
| Sep 15, 2026 | $5.90 | $5.91 | $5.635 | $5.67 | 1.61M |
| Sep 14, 2026 | $5.93 | $6.06 | $5.83 | $5.92 | 5.2M |
| Sep 11, 2026 | $6.124 | $6.125 | $5.835 | $5.86 | 2.41M |
| Sep 10, 2026 | $6.11 | $6.165 | $5.88 | $6.07 | 1.59M |
| Sep 9, 2026 | $6.38 | $6.47 | $6.14 | $6.16 | 1.43M |
| Sep 8, 2026 | $6.57 | $6.685 | $6.41 | $6.43 | 1.84M |
| Sep 4, 2026 | $6.71 | $6.72 | $6.52 | $6.56 | 1.65M |
| Sep 3, 2026 | $6.905 | $6.99 | $6.62 | $6.76 | 2.16M |
| Sep 2, 2026 | $6.56 | $6.87 | $6.535 | $6.83 | 7.72M |
| Sep 1, 2026 | $6.39 | $6.74 | $6.34 | $6.47 | 2.56M |
| Aug 31, 2026 | $6.36 | $6.375 | $6.135 | $6.37 | 2.51M |
| Aug 28, 2026 | $6.29 | $6.3591 | $6.23 | $6.32 | 1.39M |
The latest Smart Investors Daily articles mentioning BHC.
BHC research
Company profile and research snapshot.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | TD COWEN | Hold | — |
| May 1, 2026 | TRUIST SECURITIES | Hold | — |
| Apr 30, 2026 | TRUIST SECURITIES | Hold | — |
| Apr 30, 2026 | TD COWEN | Hold | — |
| Apr 29, 2026 | TD COWEN | Hold | — |
No generated briefing is available yet.
Yahoo · Sep 16, 2026
On September 8, Bausch Health Companies Inc. (NYSE:BHC) and Belgian skincare innovator YUN announced they are extending their microbiome-focused dermatology partnership into Mexico and five additional markets spanning Central and Eastern Europe and Central Asia. The move builds on a 2025 launch in Poland and lands just weeks after the company raised its full-year guidance […]
Yahoo · Sep 8, 2026
Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and YUN, a Belgian innovator in pioneering probiotherapeutical skincare products, announced the continued expansion of their strategic collaboration in Mexico and across additional EMEA markets following the 2025 launch in Poland.
Yahoo · Sep 8, 2026
Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and YUN, a Belgian innovator in pioneering probiotherapeutical skincare products, announced the continued expansion of their strategic collaboration in Mexico and across additional EMEA markets following the 2025 launch in Poland.
Yahoo · Sep 8, 2026
Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), announces that SILIQ® (brodalumab injection) is now listed under Alberta's public drug plan for eligible patients who meet the applicable reimbursement criteria.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BHC.
